In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.
The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing email@example.com with the subject line SUBSCRIBE LRG SCIENCE.
The latest issue of LRG Science is titled, "Patient-reported Treatment Responses in Known/Likely SDH-deficient GISTS: An Analysis of The Life Raft Group Observational Registry." This study highlights the very unique research role that defines The Life Raft Group. Subscribe to LRG Science by emailing firstname.lastname@example.org with the subject line SUBSCRIBE LRG SCIENCE.
PDF is available of LRG Science to print here. An oncologist in Chennai, India, 8,366 miles away from the Life Raft Group’s Wayne, New Jersey office, is running out of treatment [...]
PDF is available of LRG Science to print here. Real World Evidence in Action Although targeted medicine has brought about immense progress in cancer treatment, there are still enormous challenges [...]